Literature DB >> 20101871

Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics.

P Haentjens1, D Massaad, H Reynaert, E Peeters, A Van Meerhaeghe, S Vinken, K Poppe, B Velkeniers.   

Abstract

OBJECTIVE: To determine the prevalence of liver steatosis among asymptomatic individuals attending an out-patient clinic for a problem of overweight, and to define the discriminatory value of several characteristics for predicting liver steatosis among them. DESIGN AND PARTICIPANTS: Consecutive patients Swith a body mass index (BMI) of > or =25 kg/m2 who consented to undergo liver ultrasound and blood tests were recruited for inclusion. Receiver operating characteristic (ROC) curves were generated and statistical indices of diagnostic performance and their corresponding 95% confidence intervals (95% CI) were computed. Logistic regression analyses were performed to determine whether a combination of characteristics could improve diagnostic accuracy.
RESULTS: We enrolled sixty-eight subjects (mean BMI, 37.5 kg/m2), of whom 39 (57.4%) had liver steatosis on ultrasound. Logistic regression analyses indicated that only 3 variables were significantly and independently correlated with liver steatosis: female gender, low adiponectin levels, and high insulin resistance index. A composite index for predicting liver steatosis was calculated by summing the risk factors of female gender, low adiponectin, and insulin resistance index (FAIR score). The accuracy of this score was determined by ROC analysis to be 0.85 (95% CI, 0.74-0.96; P < 0.001). The presence of two or more risk factors (FAIR score > or =2) had a sensitivity, specificity, positive predictive value, and negative predictive value of 77%, 91%, 92%, and 74%, respectively. The likelihood ratio for a positive result was 8.43.
CONCLUSIONS: Among asymptomatic overweight individuals attending an out-patient clinic, the prevalence of liver steatosis on ultrasound is 57%. Female gender, the insulin resistance index, and low adiponectin are significant and independent predictors of liver steatosis. A combination of these three factors allows sensitivity and specificity for non alcoholic fatty liver of 77% and 91%, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20101871     DOI: 10.1179/acb.2009.084

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  11 in total

Review 1.  Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.

Authors:  Zeynel Abidin Ozturk; Abdurrahman Kadayifci
Journal:  World J Hepatol       Date:  2014-04-27

2.  Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients.

Authors:  Mohammad Bilal Siddiqui; Samarth Patel; Chandra Bhati; Trevor Reichman; Kenyada Williams; Carolyn Driscoll; Erika Liptrap; Mary E Rinella; Richard K Sterling; M Shadab Siddiqui
Journal:  Transplant Proc       Date:  2019 Jul - Aug       Impact factor: 1.066

3.  Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles.

Authors:  Edward O List; Darlene E Berryman; Kevin Funk; Adam Jara; Bruce Kelder; Feiya Wang; Michael B Stout; Xu Zhi; Liou Sun; Thomas A White; Nathan K LeBrasseur; Tamara Pirtskhalava; Tamara Tchkonia; Elizabeth A Jensen; Wenjuan Zhang; Michal M Masternak; James L Kirkland; Richard A Miller; Andrzej Bartke; John J Kopchick
Journal:  Endocrinology       Date:  2014-02-11       Impact factor: 4.736

4.  Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response.

Authors:  Astrid Spruss; Janin Henkel; Giridhar Kanuri; Daniela Blank; Gerhard P Püschel; Stephan C Bischoff; Ina Bergheim
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

Review 5.  Genetics of murine type 2 diabetes and comorbidities.

Authors:  Iqbal M Lone; Fuad A Iraqi
Journal:  Mamm Genome       Date:  2022-02-03       Impact factor: 3.224

6.  Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients.

Authors:  Pochamana Phisalprapa; Siripen Supakankunti; Phunchai Charatcharoenwitthaya; Piyaporn Apisarnthanarak; Aphinya Charoensak; Chaiwat Washirasaksiri; Weerachai Srivanichakorn; Nathorn Chaiyakunapruk
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

7.  Body Fat Changes and Liver Safety in Obese and Overweight Women Supplemented with Conjugated Linoleic Acid: A 12-Week Randomised, Double-Blind, Placebo-Controlled Trial.

Authors:  Edyta Mądry; Ida Judyta Malesza; Mehala Subramaniapillai; Agata Czochralska-Duszyńska; Marek Walkowiak; Anna Miśkiewicz-Chotnicka; Jarosław Walkowiak; Aleksandra Lisowska
Journal:  Nutrients       Date:  2020-06-17       Impact factor: 5.717

Review 8.  Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.

Authors:  Howard C Masuoka; Naga Chalasani
Journal:  Ann N Y Acad Sci       Date:  2013-01-30       Impact factor: 5.691

9.  Deepure Tea Improves High Fat Diet-Induced Insulin Resistance and Nonalcoholic Fatty Liver Disease.

Authors:  Jing-Na Deng; Juan Li; Hong-Na Mu; Yu-Ying Liu; Ming-Xia Wang; Chun-Shui Pan; Jing-Yu Fan; Fei Ye; Jing-Yan Han
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-04       Impact factor: 2.629

Review 10.  Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System.

Authors:  Mohamed H Ahmed; Sufian K Noor; Sarra O Bushara; Nazik Elmalaika Husain; Wadie M Elmadhoun; Ibrahim A Ginawi; Meissa M Osman; Abdalhafeez O Mahmoud; Ahmed O Almobarak
Journal:  Gastroenterology Res       Date:  2017-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.